Avantax Advisory Services’s TherapeuticsMD TXMD Stock Holding History

Avantax Advisory Services’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-940	Closed	-$18K	–	1392
2022 Q1	$18K	Buy	940 +320	+52%	+$5.03K	﹤0.01%	1272
2021 Q4	$11K	Sell	620 -400	-39%	-$12K	﹤0.01%	1240
2021 Q3	$38K	Sell	1,020 -20	-2%	-$888	﹤0.01%	1165
2021 Q2	$62K	Hold	1,040	–	–	﹤0.01%	1122
2021 Q1	$69K	Buy	1,040 +520	+100%	+$40.7K	﹤0.01%	1011
2020 Q4	$31K	Sell	520 -216	-29%	-$14.7K	﹤0.01%	926
2020 Q3	$59K	Buy	736 +316	+75%	+$25.2K	﹤0.01%	1333
2020 Q2	$26K	Buy	420 +160	+62%	+$9.31K	﹤0.01%	841
2020 Q1	$14K	Hold	260	–	–	﹤0.01%	792
2019 Q4	$31K	Hold	260	–	–	﹤0.01%	814
2019 Q3	$48K	Hold	260	–	–	﹤0.01%	560
2019 Q2	$34K	Buy	+260	New	+$46.6K	﹤0.01%	511

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Avantax Advisory Services's TXMD Position: Q2 2022 in Review

Avantax Advisory Services sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 940 shares — an estimated $18K sold.

Avantax Advisory Services first reported a position in TXMD in Q2 2019 and held it in 12 quarters. The position peaked at $69K in Q1 2021. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

Avantax Advisory Services reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
Avantax Advisory Services sold 940 TherapeuticsMD shares in Q2 2022, an estimated $18K.
Avantax Advisory Services first reported a position in TherapeuticsMD in Q2 2019 and held it in 12 quarters.
Avantax Advisory Services's TherapeuticsMD position peaked at $69K in Q1 2021.
53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Avantax Advisory Services's 13F filing for Q2 2022, filed 2 Aug 2022.